Shilpa Medicare informs about company updates

25 Oct 2019 Evaluate

Shilpa Medicare has informed that the Company has received US FDA Establishment Inspection Report (EIR) on 24 October 2019, for the Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at S-20 to S-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla, Telangana State, India. The company’s finished dosage form facility was inspected by US FDA from 29th August to 6th September, 2019. FDA has concluded the inspection, with determination that the inspection classification of this facility is ‘voluntary action indicated’ (VAI). This facility is in acceptable state of compliance with regards to current good manufacturing practice (CGMP). 

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

331.30 -2.65 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×